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Abstract:
Background: Daily calorie restriction regimens are still the most common diet strategies
implemented for weight loss. [2,3] In the recent years, intermittent fasting (IMF) has gained
popularity among some of the easier diets to follow.[4]
Objective: The objective of this study is to use the available data on short- and long-term effects
of intermittent fasting, either by time restricted feeding or alternate day fasting and help
healthcare providers decide on which patients should be recommended IMF as a dietary option.
Study design: Searched Google Scholar, CINAHL, PubMed and Cochrane databases for
evidence-based literature on intermittent fasting. Included studies: non-religious intermittent
fasting for the purpose of health benefits. Excluded studies: intermittent fasting for religious
reasons. Outcomes measured include systolic BP, weight loss, insulin resistance, LDL, HDL,
total cholesterol, triglycerides and inflammatory markers. Targeted audience: healthcare
providers.
Results: Results from adult human randomized controlled trials show individuals who did short
term IMF had a drop in SBP by 9.67 ± 1mmHg (p<0.001), weight loss by 5.6 ± 1 kg (95% CI: 7.4, -3.4), decrease in insulin resistance by 36 ± 10 U/mg (p=0.005), drop in LDL levels by 28±
7 mg/dL (p<0.0001) drop in triglyceride levels by 15 ± 1 mg/dL (p<0.001), drop in total
cholesterol levels by 31 ± 2 mg/dL (p<0.0001), drop in CRP levels by 1 mg/L (p=0.01) and an
increase in plasma adiponectin by 672 ± 1191 ng/mL compared to the control group. Results
from adult human randomized controlled trials show individuals who did long term IMF had a
drop in SBP by 7 ± 2mm Hg (p<0.05), weight loss by 5.2% [95% CI, -7.6% to -3.0%], drop in
HA1C by 0.7 ±1% (p<0.05), drop in LDL by 6 ± 1 mg/dL (p<0.588), increase of 6.2mg/dL [95%

CI: 0.1, -12.4] in their HDL, decrease in triglycerides by 0.3mmol/L (p<0.001), decrease in total
cholesterol by 0.78± 0.01 mmol/L (p<0.05) over control group.
Conclusion: According to these findings, even a 5-10-week period of IMF can reduce systolic
blood pressure levels, total lipid profile and inflammatory markers. Short term IMF can also
increase insulin resistance making it favorable among prediabetic and diabetic individuals. Three
months or greater of consecutively fasting can reduce systolic blood pressure levels, total lipid
profile and inflammatory markers at a steady state. The most effective way of losing weight in
overweight populations is to incorporate IMF with exercise as the health benefits are greater
(increase HDL levels). IMF long term stabilizes cardiac risk factors (lipids, BP) while further
decreasing HA1c levels and weight loss. Even though intermittent fasting might not be ideal for
everyone and further research must be done on risks vs benefits for an individual patient, IMF is
an ideal dietary option that should be recommended by healthcare providers for men and women
who are of normal weight, overweight or have type II diabetes mellitus and are interested in
lowering their insulin resistance, lipid profile, and cardiovascular risk.

Keywords: Intermittent fasting, diet, healthcare providers, time restricted feeding,
cardiovascular risk, obesity

Introduction:
In 2016, World Health Organization (WHO) reported that more than 1.9 billion adults
were overweight and over 650 million people were obese.[1] To combat this crisis, WHO
recommends clinicians target lifestyle modifications as the first line in weight loss. [1] Daily
calorie restriction regimens are still the most common diet strategies implemented for weight

loss. [2,3] Some of the common diet strategies include keto, paleo and Mediterranean diets which
focus on high protein, low carbs, low fat and plenty of vegetables and fruit. In the recent years,
intermittent fasting (IMF) has gained popularity among some of the easier diets to follow.[4] The
term intermittent fasting is defined as the reduction of calorie intake on an intermittent basis.
This could mean for several hours during the day to a complete 24-hour period. [4,5,6,7] The most
popular type of intermittent fasting is time-restricted feedings (TRF) which involves limiting
daily food intake to an 8-hour period and fasting 16 hours daily. [8,9] TRF is also popular among
physically active people due to reports on its effect on weight loss while maintaining muscle
mass. [9,10] Benefits of IMF include lowering cardiovascular risk factors (lipid profile, blood
pressure), [11-26] and its benefits for diabetes mellitus type 2. [27] However, short (8-12 weeks) and
long term (>3 months) effects of intermittent fasting in human models are not known. The
objective of this study is to use the limited data available on short- and long-term effects of
intermittent fasting and help healthcare providers decide on which patients should be
recommended IMF as a dietary option.

Methods:
The design of this study was a systematic review of evidence-based literature of the
short- and long-term effects of IMF. The review was conducted using Google Scholar, CINAHL,
PubMed and Cochrane databases to search for literature on intermittent fasting. Inclusion criteria
focused on non-religious intermittent fasting for the purpose of health benefits. Exclusion criteria
included intermittent fasting for religious reasons. In order to provide depth in this review,
studies focused on both time restricted feedings and alternate day fasting. Originally animal
studies were excluded from the research but due to low yield in research, animal studies were

also included. Searches were performed using the keywords “intermittent fasting” in
combination with “benefits”, “health outcomes” as well as “alternate day fasting” and “time
restricted feedings”. Searches were also performed for different categories including “obese men
and women”, “average weight individuals”, “diabetes mellitus” and “cardiovascular benefits”.
The outcomes measured included systolic BP, weight loss, insulin resistance, LDL, HDL, total
cholesterol, triglycerides and inflammatory markers. The short-term effects were measured if
IMF was done for less than 3 months. The long-term effects were measured if IMF continued for
more than 3 months, with more studies focusing on IMF continued for at least a year.

Results:
Table 1. Short Term Effects of Intermittent Fasting Based on Adult Human Randomized Controlled Trials
Fasting

Differences between the
two groups

Systolic BP

↓9.67 ± 1mmHg p < 0.001

Weight loss

↓5.2 ± 0.9kg, p<0.001

Insulin resistance ↓36 ± 10 U/mg p=0.005

Citation

Epi Sentence

Individuals who did IMF had a drop in SBP by ↓9.67 ±
Eshghinia et al.,
1mmHg (p<0.001) over an 8-week period compared to
2013
the control group.
Varady et. al, Individuals who did IMF had a drop-in weight loss by
2013 Hoddy et. 5.2 ± 0.9kg, p<0.001 over a 12-week period compared
al, 2016
to the control group.
Sutton et. al,
2018

Individuals who were prediabetic and diabetic and did
IMF had a decrease in insulin resistance by 36 ± 10
U/mg (p=0.005) over a 5- week period compared to
prediabetic and diabetic patients who did not IMF.

Individuals who did IMF had a drop in LDL levels by
Klempel et. al,
28± 7 mg/dL (p<0.0001) over a 10-week period
2013
compared to the control group.
HDL
N/A
N/A
No statistical significance
Individuals who did IMF had a drop-in triglyceride
Klempel et. al,
Triglycerides
↓15 ± 1 mg/dL p<0.001
levels by 15 ± 1 mg/dL (p<0.001) over a 10-week
2013
period compared to the control group.
Individuals who did IMF had a drop in total cholesterol
Klempel et. al,
Total cholesterol ↓31 ± 2 mg/dL p<0.0001
levels by 31 ± 2 mg/dL (p<0.0001) over a 10-week
2013
period compared to the control group.
Individuals who did IMF had a drop in CRP levels by 1
Varady et. al,
C-reactive protein ↓ 1± 1 mg/L p=0.01
mg/L (p=0.01) over a 12-week period compared to the
2013
control group.
Individuals who did IMF had an increase in plasma
Varady, et. al,
Plasma adiponectin ↑672 ± 1191 ng/mL P<0.01
adiponectin by 672 ± 1191 ng/mL over a 12-week
2013
period compared to the control group.
LDL

↓28± 7 mg/dL p<0.0001

Table 2. Long Term Effects of Intermittent Fasting Based on Adult Human Randomized Controlled Trials
Fasting

Differences between the
two

Citation

Epi Sentence groups

Individuals who did IMF had a drop in SBP by 7 ±
2mm Hg (p<0.05) over a 12-week period as
compared to the control group.

Systolic BP

↓7 ± 2mm Hg p< 0.05

Weight loss

Trepanowski et al,
↓5.2%
2017 Schubel et al.,
95% CI, (-7.6% to -3.0%)
2018

Individuals who did IMF had a drop-in weight loss
by 5.2% [95% CI, -7.6% to -3.0%] over a 12month period compared to the control group.

↓0.7± 1% p<0.001

Carter et al, 2016

Individuals who had type 2 DM and did IMF had a
drop in HA1C by 0.7 ±1% (p<0.05) at 12 weeks
compared to the type 2 diabetic patients who were
not on IMF.

HA1C

Gabel et. al 2018

LDL

↓6 ± 1 mg/dL p < 0.588

Bhutani et. al 2013

Individuals who did IMF had a drop in LDL by 6 ±
1 mg/dL (p<0.588) over a 12-week period as
compared to the control group. However, not
statistical significance.

HDL

↑6.2mg/dL
95% CI (0.1, -12.4)

Trepanowski et. al
2013

Individuals who did IMF with exercise had a
increase of 6.2mg/dL [95% CI: 0.1, -12.4] in their
HDL over a 12 week period than those who only
did IMF.

Triglycerides

↓0.3mmol/L p<0.001

Ash et. al, 2003

Individuals who had type 2 diabetes who did IMF
had a decrease in triglycerides by 0.3mmol/L
(p<0.001) compared to their baseline.

Total
cholesterol

↓0.78± 0.01 mmol/L
p<0.05

Hill et al. 1989

Individuals who did IMF had a decrease in total
cholesterol by 0.78± 0.01 mmol/L (p<0.05) over a
12-week period compared to those who did
continuous energy restriction.

Discussion:
This review shows IMF is an effective way for weight loss and reducing cardiovascular
risk in adult men and women of normal weight and overweight as well as prediabetic and
diabetic individuals. The primary goal of this study was to analyze the short- and long-term data
on IMF and help healthcare providers decide on which patients should be recommended IMF as
a dietary option.

As shown in table 1, five to ten-week periods of IMF can reduce systolic blood pressure
levels, total lipid profile and inflammatory markers. Short term IMF can also increase insulin
resistance making it favorable among prediabetic and diabetic individuals. Some minor side
effects were seen in men with prediabetes, these included nausea, vomiting, frequent urination,
drowsiness, increased thirst and diarrhea. No serious complications were observed [9].

As shown in table 2, three months or greater of consecutively fasting can reduce systolic
blood pressure levels, total lipid profile and inflammatory markers at a steady state. The most
effective way of losing weight in overweight populations is to incorporate IMF with exercise as
the health benefits are higher (increase HDL levels). Studies show that IMF long term, stabilizes
cardiac risk factors (lipids, BP) while further decreasing HA1c levels and weight loss. These
cardioprotective benefits were seen also in normal weight individuals as there was a reduction in
inflammatory markers and increase in adiponectin [22].
As IMF focuses on time restricted feedings, individuals have the flexibility in choosing the hours
they want to fast, and the food they want to consume, making it more attractive among a wider
population. As with any new diet, young adults and obese individuals of all ages are more
inclined to initiate diets. Therefore, when considering the ideal candidate for intermittent fasting,
clinicians must take into account their age, risk factors, safety and comorbidities. The results are
reassuring for IMF to be considered a healthy option for those who are of normal weight,
overweight and diabetic individuals with minor side effects for some populations compared to
others. However, there is not enough evidence to comfortably say that IMF is right for everyone.
Especially, for patients dependent on medication dosed with food and medically frail individuals.

Limitations of this review are: the highest magnitude of measure of association was used.
Benefits associated with IMF on boosting brain health, preventing cancer and improving
immunity were not discussed in this study because literature was only done in animal studies and
cannot be compared to human studies. There is lack of longer studies (greater than 1 year) in
human subjects that confirmed the benefits of IMF. Risks and negative outcomes of intermittent
fasting were not addressed or researched in this study.
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